Saltar al contenido
Merck

46525

Supelco

19-Norethindrone

VETRANAL®, analytical standard

Sinónimos:

17α-Ethynyl-19-nortestosterone, 17-Hydroxy-19-nor-17α-4-pregnen-20-yn-3-one, 17α-Ethynyl-17β-hydroxy-19-nor-4-androsten-3-one, 19-Nor-17α-ethynyl-4-androsten-17β-ol-3-one, 19-Norethisterone

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización


About This Item

Fórmula empírica (notación de Hill):
C20H26O2
Número de CAS:
Peso molecular:
298.42
Beilstein:
1915671
Número CE:
Número MDL:
Código UNSPSC:
41116107
ID de la sustancia en PubChem:
NACRES:
NA.24

grado

analytical standard

Nivel de calidad

Línea del producto

VETRANAL®

caducidad

limited shelf life, expiry date on the label

técnicas

HPLC: suitable
gas chromatography (GC): suitable

mp

205-206 °C (lit.)

aplicaciones

pharmaceutical (small molecule)

Formato

neat

cadena SMILES

[H][C@]12CCC(=O)C=C1CC[C@]3([H])[C@]2([H])CC[C@@]4(C)[C@@]3([H])CC[C@@]4(O)C#C

InChI

1S/C20H26O2/c1-3-20(22)11-9-18-17-6-4-13-12-14(21)5-7-15(13)16(17)8-10-19(18,20)2/h1,12,15-18,22H,4-11H2,2H3/t15-,16+,17+,18-,19-,20-/m0/s1

Clave InChI

VIKNJXKGJWUCNN-XGXHKTLJSA-N

Información sobre el gen

human ... PGR(5241)

¿Está buscando productos similares? Visita Guía de comparación de productos

Aplicación

Refer to the product′s Certificate of Analysis for more information on a suitable instrument technique. Contact Technical Service for further support.

Acciones bioquímicas o fisiológicas

19-norethindrone is an oral contraceptive involved in the inhibition of cytosolic sulfotransferases (SULT).

Información legal

VETRANAL is a registered trademark of Merck KGaA, Darmstadt, Germany

Pictogramas

Health hazardEnvironment

Palabra de señalización

Danger

Frases de peligro

Clasificaciones de peligro

Aquatic Acute 1 - Aquatic Chronic 1 - Carc. 2 - Lact. - Repr. 1A

Código de clase de almacenamiento

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

Clase de riesgo para el agua (WGK)

WGK 3

Equipo de protección personal

dust mask type N95 (US), Eyeshields, Gloves


Elija entre una de las versiones más recientes:

Certificados de análisis (COA)

Lot/Batch Number

¿No ve la versión correcta?

Si necesita una versión concreta, puede buscar un certificado específico por el número de lote.

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Karl van den Broeck et al.
The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception, 17(5), 321-328 (2012-09-15)
Ferdinand Peeters, a practising gynaecologist from Turnhout, near Antwerp (Belgium), had a pivotal role in the development of a practical and viable modality of oral contraception, striking the balance between efficacy and an acceptably low incidence and severity of side
Chelsea B Polis et al.
The Lancet. Infectious diseases, 13(9), 797-808 (2013-07-23)
Whether or not the use of hormonal contraception affects risk of HIV acquisition is an important question for public health. We did a systematic review, searching PubMed and Embase, aiming to explore the possibility of an association between various forms
Patricia M LoRusso et al.
Cancer chemotherapy and pharmacology, 71(1), 193-202 (2012-10-16)
Vismodegib, a first-in-class oral hedgehog pathway inhibitor, is an effective treatment for advanced basal cell carcinoma. Based on in vitro data, a clinical drug-drug interaction (DDI) assessment of cytochrome P450 (CYP) 2C8 was necessary; vismodegib's teratogenic potential warranted a DDI
Derin J Cobia et al.
Schizophrenia research, 139(1-3), 1-6 (2012-06-01)
Cortical abnormalities are considered a neurobiological characteristic of schizophrenia. However, the pattern of such deficits as they progress over the illness remains poorly understood. The goal of this project was to assess the progression of cortical thinning in frontal and
Isabelle Demeestere et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 31(7), 903-909 (2012-11-07)
To assess the efficacy of gonadotropin-releasing hormone agonist (GnRHa) in preventing chemotherapy-induced ovarian failure in patients treated for Hodgkin or non-Hodgkin lymphoma within the setting of a multicenter, randomized, prospective trial. Patients age 18 to 45 years were randomly assigned

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico